Aberrant overexpression of BAZ2A correlates well with recurrence in prostate cancer and is also linked with maintaining prostate cancer cell growth.114 BAZ2B has been predicted to be difficult in terms of druggability analysis.28 Owing to the significant therapeutic potential in developing BAZ2A/BAZ2B inhibitors/chemical Drouin et al.113 sought to develop a potent, selective and cell active chemical probe through structure based discovery starting from hit compound 33 (reference compound 1, Fig. 15). The gene discussed is BAZ2B; the disease is prostate cancer.